Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation

Simple item page
dc.article.start-page4153en_ZA
dc.citation.doi10.3390/ijms22084153en_ZA
dc.contributor.authorXulu, Kutlwano R.
dc.contributor.authorAugustine, Tanya N.
dc.date.accessioned2021-08-13T07:47:53Z
dc.date.available2021-08-13T07:47:53Z
dc.date.issued2021-04-16
dc.description.abstractThromboembolic complications are a leading cause of morbidity and mortality in cancer patients. Cancer patients often present with an increased risk for thrombosis including hypercoagulation, so the application of antiplatelet strategies to oncology warrants further investigation. This study investigated the effects of anastrozole and antiplatelet therapy (aspirin/clopidogrel cocktail or atopaxar) treatment on the tumour responses of luminal phenotype breast cancer cells and induced hypercoagulation. Ethical clearance was obtained (M150263). Blood was co-cultured with breast cancer cell lines (MCF7 and T47D) pre-treated with anastrozole and/or antiplatelet drugs for 24 h. Hypercoagulation was indicated by thrombin production and platelet activation (morphological and molecular). Gene expression associated with the epithelial-to-mesenchymal transition (EMT) was assessed in breast cancer cells, and secreted cytokines associated with tumour progression were evaluated. Data were analysed with the PAST3 software. Our findings showed that antiplatelet therapies (aspirin/clopidogrel cocktail and atopaxar) combined with anastrozole failed to prevent hypercoagulation and induced evidence of a partial EMT. Differences in tumour responses that modulate tumour aggression were noted between breast cancer cell lines, and this may be an important consideration in the clinical management of subphenotypes of luminal phenotype breast cancer. Further investigation is needed before this treatment modality (combined hormone and antiplatelet therapy) can be considered for managing tumour associated-thromboembolic disorder.en_ZA
dc.description.librarianLTM2021en_ZA
dc.facultyFaculty of Health Sciencesen_ZA
dc.funderWits Open Access Publishing Funden_ZA
dc.identifier.citationXulu K. R. and Augustine T. N. Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation. Vol. 22, International Journal of Molecular Sciences. 2021. DOI: 10.3390/ijms22084153en_ZA
dc.identifier.urihttps://hdl.handle.net/10539/31498
dc.journal.issue8en_ZA
dc.journal.linkhttps://www.mdpi.com/journal/ijmsen_ZA
dc.journal.titleInternational Journal of Molecular Sciencesen_ZA
dc.journal.volume22en_ZA
dc.language.isoenen_ZA
dc.publisherMDPIen_ZA
dc.schoolSchool of Anatomical Sciencesen_ZA
dc.subjectBreast canceren_ZA
dc.subjectHypercoagulationen_ZA
dc.subjectAspirinen_ZA
dc.subjectClopidogrelen_ZA
dc.subjectAtopaxaren_ZA
dc.subjectAnastrozoleen_ZA
dc.subjectPlatelet activationen_ZA
dc.subjectThrombin activityen_ZA
dc.subjectTumour survivalen_ZA
dc.titleAntiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulationen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
K.Xulu_T.Augustine (2021)_ijms-22-04153-v2-1.pdf
Size:
5.49 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
*School of Anatomical Sciences (Journal Articles)
Wits Research Outputs